3 of 50
CEO runner-up: Mitch Gold
CEO, Dendreon

For the 192,000 men diagnosed with prostate cancer last year, Dr. Mitch Gold's Seattle-based BioTech company Dendreon may hold the key to their survival. The Food and Drug Administration last April finally approved Provenge, a prostate cancer vaccine that stimulates the body's own immune system to attack tumors. In one clinical trial, Provenge extended the lives of patients with prostate cancer on average by 4.1 months, with 32% of patients still alive three years after treatment. While Gold and Dendreon stand to benefit -- it's estimated Provenge could generate more than $1 billion in U.S. sales -- ultimately the real beneficiaries will be the patients themselves. --J.P.M.

NEXT: CEO runner-up: Jack Ma
Last updated July 09 2010: 1:19 PM ET
More Galleries
10 things I learned at the New York auto show Auto shows these days are about as relevant as a dashboard cigarette lighter. But a careful observer can still pick up a thing or two. More
50 years of the Ford Mustang Take a drive down memory lane with our favorite photos of the car through the years. More
8 CEOs who took a pay cut in 2013 Median CEO pay inched up 9% in 2013 to $13.9 million. But not everyone got a bump last year. Here are eight CEOs who missed out. More
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.